4.6 Article

Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler

期刊

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 104, 期 -, 页码 180-187

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejps.2017.03.035

关键词

Andersen Cascade impactor; Easyhaler; Formoterol; Inhaled volume; Maximum inhalation flow

资金

  1. Ahnirall
  2. AstraZeneca
  3. Boehringer Ingelheim
  4. Chiesi
  5. GlaxoSmithKline
  6. Innovata Biomed
  7. Meda
  8. Napp Pharmaceuticals
  9. Mundipharma
  10. NorPharma
  11. Norvartis
  12. Orion
  13. Sanofi
  14. Teva
  15. Truddell Medical International
  16. UCB
  17. Zentiva
  18. EPSRC
  19. MRC

向作者/读者索取更多资源

Most patients using dry powder inhalers (DPIs) do not achieve the inhalation parameters recommended for pharmacopoeial in-vitro dose emission testing. The dose emission characteristics of formoterol from an Easyhaler((R)) have been measured using the Andersen Cascade Impactor (ACI) with a maximum inhalation flow (MIF) of 28.3, 60 and 90 L/min and inhaled volumes (Vin) of 240, 750, 1500 and 2000 mL. The total emitted dose (TED) was significantly higher at 90 L/min (p < 0.05), but the difference in the TED between low (28.3 L/min) and high (90 L/min) flow rate was significantly reduced by increasing the Vin. The fine particle dose (FPD) was higher (p < 0.05) at 90 L/min for all Vin values compared to 28.3 and 60 L/min. Similarly the mass median aerodynamic diameter (MMAD) was smaller at 90 L/min across all Vin values. Dose emission characteristics were lower at 240 mL for both 1VIIFs. The results for 240 mL could be due to an insufficient Vin pulled through the ACI or incomplete emptying of the dose metering cup. This study shows that the FPD, %FPF and MMAD were not significantly affected by the vin >= 750 mL and that an inhaled volume as low as 750 mL could be used with the ACI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据